Novo Nordisk reports 2025 sales growth, cuts 2026 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
February 3, 2026 12:05 PM ESTNovo Nordisk (NYSE: NVO) reported Q4 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of $11.99 billion.
GUIDANCE:
Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B... More
